Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?

Karen Kelly, Jr P.A. Bunn

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Brain metastases from non-small cell lung cancer develop in approximately one-third of patients. If not treated, neurological deterioration occurs quickly. Treatment with whole brain irradiation is advisable to palliate symptoms but despite this treatment, survival remains poor at 3-6 months. Recently, aggressive approaches with surgical resection and stereotactic radiosurgery have dramatically improved the control of brain metastases resulting in a meaningful survival advantage for a subset of eligible patients. New evidence also suggests a possible role for chemotherapy in the treatment of brain metastases. With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category. Copyright (C) 1998 Elsevier Science Ireland Ltd.

Original languageEnglish (US)
Pages (from-to)85-91
Number of pages7
JournalLung Cancer
Volume20
Issue number2
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Brain
Therapeutics
Survival
Radiosurgery
Patient Selection
Drug Therapy

Keywords

  • Brain metastases
  • Non-small cell lung cancer
  • Treatment

ASJC Scopus subject areas

  • Oncology

Cite this

Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer? / Kelly, Karen; P.A. Bunn, Jr.

In: Lung Cancer, Vol. 20, No. 2, 1998, p. 85-91.

Research output: Contribution to journalArticle

@article{8ee96c54585349caa7daff26a2ba3d10,
title = "Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?",
abstract = "Brain metastases from non-small cell lung cancer develop in approximately one-third of patients. If not treated, neurological deterioration occurs quickly. Treatment with whole brain irradiation is advisable to palliate symptoms but despite this treatment, survival remains poor at 3-6 months. Recently, aggressive approaches with surgical resection and stereotactic radiosurgery have dramatically improved the control of brain metastases resulting in a meaningful survival advantage for a subset of eligible patients. New evidence also suggests a possible role for chemotherapy in the treatment of brain metastases. With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category. Copyright (C) 1998 Elsevier Science Ireland Ltd.",
keywords = "Brain metastases, Non-small cell lung cancer, Treatment",
author = "Karen Kelly and {P.A. Bunn}, Jr",
year = "1998",
doi = "10.1016/S0169-5002(98)00020-8",
language = "English (US)",
volume = "20",
pages = "85--91",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?

AU - Kelly, Karen

AU - P.A. Bunn, Jr

PY - 1998

Y1 - 1998

N2 - Brain metastases from non-small cell lung cancer develop in approximately one-third of patients. If not treated, neurological deterioration occurs quickly. Treatment with whole brain irradiation is advisable to palliate symptoms but despite this treatment, survival remains poor at 3-6 months. Recently, aggressive approaches with surgical resection and stereotactic radiosurgery have dramatically improved the control of brain metastases resulting in a meaningful survival advantage for a subset of eligible patients. New evidence also suggests a possible role for chemotherapy in the treatment of brain metastases. With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category. Copyright (C) 1998 Elsevier Science Ireland Ltd.

AB - Brain metastases from non-small cell lung cancer develop in approximately one-third of patients. If not treated, neurological deterioration occurs quickly. Treatment with whole brain irradiation is advisable to palliate symptoms but despite this treatment, survival remains poor at 3-6 months. Recently, aggressive approaches with surgical resection and stereotactic radiosurgery have dramatically improved the control of brain metastases resulting in a meaningful survival advantage for a subset of eligible patients. New evidence also suggests a possible role for chemotherapy in the treatment of brain metastases. With several options now available to treat brain metastases proper patient selection is needed. This article will stratify patients with brain metastases and discuss the treatment modalities for each category. Copyright (C) 1998 Elsevier Science Ireland Ltd.

KW - Brain metastases

KW - Non-small cell lung cancer

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=0031904419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031904419&partnerID=8YFLogxK

U2 - 10.1016/S0169-5002(98)00020-8

DO - 10.1016/S0169-5002(98)00020-8

M3 - Article

C2 - 9711526

AN - SCOPUS:0031904419

VL - 20

SP - 85

EP - 91

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -